Press Releases Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
16.76 ^USD	-11.09%		-8.47%	-10.85%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

Press Releases

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	07-08	BU
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran	06-23	BU
Arrowhead Pharmaceuticals : ERA 2025 ARO C3	06-06	PU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity	06-02	BU
Arrowhead Pharmaceuticals : NLA 2025 SHASTA 5 AP Study Design	05-30	PU
Arrowhead Pharmaceuticals : NLA 2025 PALISADE AP QOL FCS	05-30	PU
Arrowhead Pharmaceuticals : NLA 2025 ARO DIMER PA	05-29	PU
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences	05-29	BU
Arrowhead Pharmaceuticals : TIDES USA 2025 CNS	05-22	PU
Arrowhead Pharmaceuticals : ATS 2025 RAGE Preclinical 1	05-19	PU
Arrowhead Pharmaceuticals : ATS 2025 RAGE Preclinical 2	05-19	PU
Arrowhead Pharmaceuticals : ARWR FQ2 2025 Script FINAL	05-12	PU
Arrowhead Pharmaceuticals : ECO2025 ALK7	05-12	PU
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results	05-12	BU
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences	05-07	BU
Arrowhead Pharmaceuticals : EAS 2025 GATEWAY	05-07	PU
Arrowhead Pharmaceuticals : EAS 2025 PALISADE	05-07	PU
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results	04-30	BU
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer	04-15	BU
Arrowhead Pharmaceuticals : Corporate Presentation Short April 2025 Final	04-15	PU
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	04-07	AQ
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	04-04	BU
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy	03-10	BU
Arrowhead Pharmaceuticals : RNA Leaders Europe 2025 Obesity View Presentation	03-06	PU
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases	03-06	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Press Releases

Filters